Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2008

01.12.2008 | Gastrointestinal Oncology

Preoperative Serum Carcinoembryonic Antigen Level as a Predictive Factor of Recurrence After Curative Resection of Colorectal Cancer

verfasst von: Ryo Takagawa, MD, Syoichi Fujii, MD, PhD, Mitsuyoshi Ohta, MD, PhD, Yasuhiko Nagano, MD, PhD, Chikara Kunisaki, MD, PhD, Shigeru Yamagishi, MD, PhD, Shunichi Osada, MD, PhD, Yasushi Ichikawa, MD, PhD, Hiroshi Shimada, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

We evaluated the prognostic value of the preoperative serum carcinoembryonic antigen (CEA) level in patients with colorectal cancer (CRC).

Patients and Methods

The study group comprised 638 patients. The optimal cutoff value for the preoperative serum CEA level was determined. Predictive factors of recurrence were evaluated using multivariate analyses. The relapse-free time was investigated according to the CEA level.

Results

All patients underwent potentially curative resection for CRC without distant metastasis, classified as stage I, II, or III. The optimal cutoff value for preoperative serum CEA level was 10 ng/ml. Elevated preoperative serum CEA level was observed in 92 patients. Multivariate analysis identified tumor–node–metastasis (TNM) stage and preoperative serum CEA level as independent predictive factors of recurrence. The relapse-free survival between CEA levels >10 ng/ml and <10 ng/ml significantly differed in patients with stage II and III. However, there was no significant difference in relapse-free survival between CEA levels >10 ng/ml and <10 ng/ml in patients with stage I.

Conclusion

Preoperative serum CEA is a reliable predictive factor of recurrence after curative surgery in CRC patients and a useful indicator of the optimal treatment after resection, particularly for cases classified as stage II or stage III.
Literatur
1.
Zurück zum Zitat Marugame M, Kamo K-I, Katanoda K, et al. Cancer incidence and incidence rate in Japan in 1999: estimates based on data from 11 population-based cancer registries. Jpn J Clin Oncol 2004;34: 352–6.CrossRef Marugame M, Kamo K-I, Katanoda K, et al. Cancer incidence and incidence rate in Japan in 1999: estimates based on data from 11 population-based cancer registries. Jpn J Clin Oncol 2004;34: 352–6.CrossRef
2.
Zurück zum Zitat Japanese Society for Cancer of the Colon and Rectum: multi-institutional of Large Bowel Cancer in Japan, Cause treated in 1995–1998. Vol 17 (1999), Vol 18 (2000), Vol 21 (2001), Vol 24 (2003). Kinbara, Tokyo, Japan Japanese Society for Cancer of the Colon and Rectum: multi-institutional of Large Bowel Cancer in Japan, Cause treated in 1995–1998. Vol 17 (1999), Vol 18 (2000), Vol 21 (2001), Vol 24 (2003). Kinbara, Tokyo, Japan
3.
Zurück zum Zitat Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil as adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;32: 352–8. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil as adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;32: 352–8.
4.
Zurück zum Zitat Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: result from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11: 1879–87.PubMed Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: result from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11: 1879–87.PubMed
5.
Zurück zum Zitat International Multicentre Pooled Analysis of Colon Cancer Trial (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345: 937–44.CrossRef International Multicentre Pooled Analysis of Colon Cancer Trial (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345: 937–44.CrossRef
6.
Zurück zum Zitat O’Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16: 295–300.PubMed O’Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16: 295–300.PubMed
7.
Zurück zum Zitat Andre T, Boni C, Gramont A, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med 2004; 350: 2343–51.PubMedCrossRef Andre T, Boni C, Gramont A, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med 2004; 350: 2343–51.PubMedCrossRef
8.
Zurück zum Zitat Twelves C, Wong A, Scheithauer W, et al. Capecitabine as adjuvant treatment for stage III colon cancer. New Engl J Med 2005;352: 2696–704.PubMedCrossRef Twelves C, Wong A, Scheithauer W, et al. Capecitabine as adjuvant treatment for stage III colon cancer. New Engl J Med 2005;352: 2696–704.PubMedCrossRef
9.
Zurück zum Zitat de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;22: 229–37. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;22: 229–37.
10.
Zurück zum Zitat Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355: 1041–7.PubMedCrossRef Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355: 1041–7.PubMedCrossRef
11.
Zurück zum Zitat Herwits H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: 2335–42.CrossRef Herwits H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: 2335–42.CrossRef
12.
Zurück zum Zitat Wood CB, Ratcliffe JG, Burt RW, et al. The clinical significance of the pattern of elevated serum carcinoembryonic antigen (CEA) levels in recurrent colorectal cancer. Br J Surg 1980;67: 46–48.PubMedCrossRef Wood CB, Ratcliffe JG, Burt RW, et al. The clinical significance of the pattern of elevated serum carcinoembryonic antigen (CEA) levels in recurrent colorectal cancer. Br J Surg 1980;67: 46–48.PubMedCrossRef
13.
Zurück zum Zitat Wichmann MW, Müller C, Lau-Werner U, et al. The role of carcinoembryonic antigen for the detection of recurrent disease following curative resection of large-bowel cancer. Langenbecks Arch Surg 2000;385: 271–5.PubMedCrossRef Wichmann MW, Müller C, Lau-Werner U, et al. The role of carcinoembryonic antigen for the detection of recurrent disease following curative resection of large-bowel cancer. Langenbecks Arch Surg 2000;385: 271–5.PubMedCrossRef
14.
Zurück zum Zitat Chau I, Allen MJ, Cunningham D, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004;22: 1420–9.PubMedCrossRef Chau I, Allen MJ, Cunningham D, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004;22: 1420–9.PubMedCrossRef
15.
Zurück zum Zitat McCall JL, Black RB, Toouli J, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 1994;37: 875–81.PubMedCrossRef McCall JL, Black RB, Toouli J, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 1994;37: 875–81.PubMedCrossRef
16.
Zurück zum Zitat Wanebo HJ, Rao B, Pinsky CM. The use of preoperative carcinoembryonic antigen level as a prognostic indicator to complement pathological staging. N Engl J Med 1978;299: 448–51.PubMed Wanebo HJ, Rao B, Pinsky CM. The use of preoperative carcinoembryonic antigen level as a prognostic indicator to complement pathological staging. N Engl J Med 1978;299: 448–51.PubMed
17.
Zurück zum Zitat Wichmann MW, Lau-Werner U, Müller C, et al. Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer. Anticancer Res 2000;20: 4953–5.PubMed Wichmann MW, Lau-Werner U, Müller C, et al. Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer. Anticancer Res 2000;20: 4953–5.PubMed
18.
Zurück zum Zitat Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005;23: 338–51.PubMed Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005;23: 338–51.PubMed
19.
Zurück zum Zitat Lipská L, Visokai V, Levý M, et al. Tumor markers in patients with relapse of colorectal carcinoma. Anticancer Res 2007;27: 1901–5.PubMed Lipská L, Visokai V, Levý M, et al. Tumor markers in patients with relapse of colorectal carcinoma. Anticancer Res 2007;27: 1901–5.PubMed
20.
Zurück zum Zitat Watine J, Miedouge M, Friedberg B. Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases: a systematic review. Dis Colon Rectum 2001;44: 1791–9.PubMedCrossRef Watine J, Miedouge M, Friedberg B. Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases: a systematic review. Dis Colon Rectum 2001;44: 1791–9.PubMedCrossRef
21.
Zurück zum Zitat Wiratkapun S, Kraemer M, Eu KW, et al. High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. Dis Colon Rectum 2004;44: 231–5.CrossRef Wiratkapun S, Kraemer M, Eu KW, et al. High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. Dis Colon Rectum 2004;44: 231–5.CrossRef
22.
Zurück zum Zitat Gold P, Freedman SO. Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121: 439–62.PubMedCrossRef Gold P, Freedman SO. Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121: 439–62.PubMedCrossRef
23.
Zurück zum Zitat Moertel CG, O’Fallon JR, Go VLW, et al. The preoperative carcinoembryonic antigen test in the diagnosis, staging and prognosis of colorectal cancer. Cancer 1986;58: 603–10.PubMedCrossRef Moertel CG, O’Fallon JR, Go VLW, et al. The preoperative carcinoembryonic antigen test in the diagnosis, staging and prognosis of colorectal cancer. Cancer 1986;58: 603–10.PubMedCrossRef
24.
Zurück zum Zitat Harrison LE, Guillem JG, Cohen AM, et al. Preoperative carcinoembryonic antigen predict outcomes in node-negative colon cancer patients: A multivariate analysis of 512 patients. J Am Coll Surg 1997;185: 55–9.PubMed Harrison LE, Guillem JG, Cohen AM, et al. Preoperative carcinoembryonic antigen predict outcomes in node-negative colon cancer patients: A multivariate analysis of 512 patients. J Am Coll Surg 1997;185: 55–9.PubMed
25.
Zurück zum Zitat Slentz K, Senagore A, Hibert J, et al. Can preoperative and postoperative CEA predict survival after colon cancer resection? Am Surg 1994;60: 528–32.PubMed Slentz K, Senagore A, Hibert J, et al. Can preoperative and postoperative CEA predict survival after colon cancer resection? Am Surg 1994;60: 528–32.PubMed
26.
Zurück zum Zitat Wang JY, Lu CY, Hsieh JS, et al. Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res 2007;39: 245–50.PubMedCrossRef Wang JY, Lu CY, Hsieh JS, et al. Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res 2007;39: 245–50.PubMedCrossRef
27.
Zurück zum Zitat Behbehani AI, Al-Sayer H, Farghaly M, et al. Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait. Int J Biol Markers 2000;15: 51–5.PubMed Behbehani AI, Al-Sayer H, Farghaly M, et al. Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait. Int J Biol Markers 2000;15: 51–5.PubMed
28.
Zurück zum Zitat Julia ML, Cassandra MM, Jennifer EH, et al. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res 2006;12: 417–23.CrossRef Julia ML, Cassandra MM, Jennifer EH, et al. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res 2006;12: 417–23.CrossRef
29.
Zurück zum Zitat Sadahiro S, Suzuki T, Makuuchi H, et al. Detection of carcinoembryonic antigen messenger RNA-expressing cells in peripheral blood 7 days after curative surgery is a novel prognostic factor in colorectal cancer. Ann Surg Oncol 2006;14: 1092–8.CrossRef Sadahiro S, Suzuki T, Makuuchi H, et al. Detection of carcinoembryonic antigen messenger RNA-expressing cells in peripheral blood 7 days after curative surgery is a novel prognostic factor in colorectal cancer. Ann Surg Oncol 2006;14: 1092–8.CrossRef
30.
Zurück zum Zitat Park JY, Lee KH. Carcinoembryonic antigen and patterns of recurrence after curative resection of the colorectal cancer. Hepatogastroenterology 2007;54: 1966–9.PubMed Park JY, Lee KH. Carcinoembryonic antigen and patterns of recurrence after curative resection of the colorectal cancer. Hepatogastroenterology 2007;54: 1966–9.PubMed
31.
Zurück zum Zitat Eggington S, Tappenden P, Pandor A, et al. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer 2006;95: 1195–201.PubMedCrossRef Eggington S, Tappenden P, Pandor A, et al. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer 2006;95: 1195–201.PubMedCrossRef
32.
Zurück zum Zitat Aballéa S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 2007;109: 1082–9.PubMedCrossRef Aballéa S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 2007;109: 1082–9.PubMedCrossRef
33.
Zurück zum Zitat Aballéa S, Boler A, Craig A, et al. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). Eur J Cancer 2007;43: 1687–93.PubMedCrossRef Aballéa S, Boler A, Craig A, et al. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). Eur J Cancer 2007;43: 1687–93.PubMedCrossRef
Metadaten
Titel
Preoperative Serum Carcinoembryonic Antigen Level as a Predictive Factor of Recurrence After Curative Resection of Colorectal Cancer
verfasst von
Ryo Takagawa, MD
Syoichi Fujii, MD, PhD
Mitsuyoshi Ohta, MD, PhD
Yasuhiko Nagano, MD, PhD
Chikara Kunisaki, MD, PhD
Shigeru Yamagishi, MD, PhD
Shunichi Osada, MD, PhD
Yasushi Ichikawa, MD, PhD
Hiroshi Shimada, MD, PhD
Publikationsdatum
01.12.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0168-8

Weitere Artikel der Ausgabe 12/2008

Annals of Surgical Oncology 12/2008 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.